Candriam S.C.A. Invests $8.36 Million in Enliven Therapeutics, Inc. $ELVN

Candriam S.C.A. purchased a new stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 416,650 shares of the company’s stock, valued at approximately $8,358,000. Candriam S.C.A. owned approximately 0.85% of Enliven Therapeutics as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of the business. Quantbot Technologies LP acquired a new stake in Enliven Therapeutics in the 1st quarter worth about $60,000. KLP Kapitalforvaltning AS increased its holdings in shares of Enliven Therapeutics by 58.1% during the second quarter. KLP Kapitalforvaltning AS now owns 6,800 shares of the company’s stock worth $136,000 after purchasing an additional 2,500 shares during the period. BIT Capital GmbH acquired a new stake in shares of Enliven Therapeutics in the first quarter valued at approximately $382,000. Invesco Ltd. boosted its stake in shares of Enliven Therapeutics by 39.6% in the first quarter. Invesco Ltd. now owns 21,044 shares of the company’s stock valued at $414,000 after buying an additional 5,972 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Enliven Therapeutics by 8.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,729 shares of the company’s stock valued at $428,000 after buying an additional 1,693 shares during the period. 95.08% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have commented on ELVN. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday, October 8th. Wall Street Zen raised Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $41.20.

Enliven Therapeutics Price Performance

Shares of NASDAQ:ELVN opened at $22.07 on Friday. Enliven Therapeutics, Inc. has a 1 year low of $13.30 and a 1 year high of $26.48. The stock has a market capitalization of $1.31 billion, a price-to-earnings ratio of -11.99 and a beta of 0.80. The company’s 50 day simple moving average is $20.23 and its 200 day simple moving average is $20.07.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Wednesday, November 12th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.11. As a group, analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Insiders Place Their Bets

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 3,250 shares of the business’s stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $20.40, for a total transaction of $66,300.00. Following the completion of the transaction, the chief financial officer owned 23,000 shares of the company’s stock, valued at approximately $469,200. The trade was a 12.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Joseph P. Lyssikatos sold 12,500 shares of the stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $22.08, for a total transaction of $276,000.00. Following the completion of the transaction, the insider directly owned 915,188 shares of the company’s stock, valued at $20,207,351.04. This trade represents a 1.35% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 99,984 shares of company stock valued at $2,021,749 in the last quarter. Corporate insiders own 25.90% of the company’s stock.

Enliven Therapeutics Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.